CGT biotherapy industry represented by stem cell therapy and immune cell therapy is considered to be a revolutionary therapeutic industry succeeding small molecule drugs and protein drugs. It demonstrates satisfactory therapeutic effects in a variety of indications which cannot be solved by traditional drugs, providing an opportunity for China to get an upper hand in the biomedical field.

Currently many CGT achievements were born from colleges and universities which mainly provide basic research platforms in the early stage, while corporate development requires production amplification in a later stage. Many start-ups based on achievements from universities need to build their own pilot transformation platforms, unable to cross the industrial death valley lying ahead due to heavy hardware investment and insufficient personnel experience of software team (or production team, QA team, etc.). To promote the development of CGT along with other biotherapeutic technologies in the field of eye diseases and facilitate the industrialization process of relevant technologies, China Eye Valley plans to establish the first comprehensive biotherapeutic platform applied to treatment of eye diseases in China. The establishment of this platform will provide production environment and equipment at GMP level for various biotherapeutic drugs, helping enterprises to establish relevant quality control system, accomplish industrial mass production from laboratory research, and complete preliminary verification of clinical effectiveness and safety with shortest time and lowest cost. In this way the entrepreneurial threshold of pilot scale-up from achievement transformation of universities is lowered, making it the core hardware for promoting rapid eco-development of industry. In the meantime it can also provide relevant hospital resources such as Wenzhou Eye Hospital, break down the barriers between enterprises and hospitals, so as to accelerate the clinical application and industrial transformation of various biotherapies in the field of eye disease treatments.